ID   CRY2_HUMAN              Reviewed;         593 AA.
AC   Q49AN0; B4DH32; B4DZD6; O75148; Q8IV71;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   28-NOV-2006, sequence version 2.
DT   28-JUN-2023, entry version 158.
DE   RecName: Full=Cryptochrome-2;
GN   Name=CRY2; Synonyms=KIAA0658;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CHARACTERIZATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=8909283; DOI=10.1021/bi962209o;
RA   Hsu D.S., Zhao X., Zhao S., Kazantsev A., Wang R.-P., Todo T., Wei Y.-F.,
RA   Sancar A.;
RT   "Putative human blue-light photoreceptors hCRY1 and hCRY2 are
RT   flavoproteins.";
RL   Biochemistry 35:13871-13877(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 5-593 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [6]
RP   TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RX   PubMed=9801304; DOI=10.1093/nar/26.22.5086;
RA   Kobayashi K., Kanno S., Smit B., van der Horst G.T.J., Takao M., Yasui A.;
RT   "Characterization of photolyase/blue-light receptor homologs in mouse and
RT   human cells.";
RL   Nucleic Acids Res. 26:5086-5092(1998).
RN   [7]
RP   FUNCTION.
RX   PubMed=10531061; DOI=10.1126/science.286.5440.768;
RA   Griffin E.A. Jr., Staknis D., Weitz C.J.;
RT   "Light-independent role of CRY1 and CRY2 in the mammalian circadian
RT   clock.";
RL   Science 286:768-771(1999).
RN   [8]
RP   UBIQUITINATION.
RX   PubMed=11889036; DOI=10.1093/emboj/21.6.1301;
RA   Yagita K., Tamanini F., Yasuda M., Hoeijmakers J.H., van der Horst G.T.,
RA   Okamura H.;
RT   "Nucleocytoplasmic shuttling and mCRY-dependent inhibition of
RT   ubiquitylation of the mPER2 clock protein.";
RL   EMBO J. 21:1301-1314(2002).
RN   [9]
RP   FUNCTION.
RX   PubMed=14672706; DOI=10.1016/j.bbrc.2003.11.099;
RA   Kawamoto T., Noshiro M., Sato F., Maemura K., Takeda N., Nagai R.,
RA   Iwata T., Fujimoto K., Furukawa M., Miyazaki K., Honma S., Honma K.I.,
RA   Kato Y.;
RT   "A novel autofeedback loop of Dec1 transcription involved in circadian
RT   rhythm regulation.";
RL   Biochem. Biophys. Res. Commun. 313:117-124(2004).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH PPP5C.
RX   PubMed=16790549; DOI=10.1073/pnas.0604138103;
RA   Partch C.L., Shields K.F., Thompson C.L., Selby C.P., Sancar A.;
RT   "Posttranslational regulation of the mammalian circadian clock by
RT   cryptochrome and protein phosphatase 5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10467-10472(2006).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY, UBIQUITINATION BY FBXL3, AND
RP   INTERACTION WITH FBXL3.
RX   PubMed=17463251; DOI=10.1126/science.1141194;
RA   Busino L., Bassermann F., Maiolica A., Lee C., Nolan P.M., Godinho S.I.,
RA   Draetta G.F., Pagano M.;
RT   "SCFFbxl3 controls the oscillation of the circadian clock by directing the
RT   degradation of cryptochrome proteins.";
RL   Science 316:900-904(2007).
RN   [12]
RP   ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND UBIQUITINATION.
RX   PubMed=22798407; DOI=10.1126/science.1223710;
RA   Hirota T., Lee J.W., St John P.C., Sawa M., Iwaisako K., Noguchi T.,
RA   Pongsawakul P.Y., Sonntag T., Welsh D.K., Brenner D.A., Doyle F.J. III,
RA   Schultz P.G., Kay S.A.;
RT   "Identification of small molecule activators of cryptochrome.";
RL   Science 337:1094-1097(2012).
RN   [13]
RP   REVIEW.
RX   PubMed=23303907; DOI=10.1152/physrev.00016.2012;
RA   Eckel-Mahan K., Sassone-Corsi P.;
RT   "Metabolism and the circadian clock converge.";
RL   Physiol. Rev. 93:107-135(2013).
RN   [14]
RP   REVIEW.
RX   PubMed=23916625; DOI=10.1016/j.tcb.2013.07.002;
RA   Partch C.L., Green C.B., Takahashi J.S.;
RT   "Molecular architecture of the mammalian circadian clock.";
RL   Trends Cell Biol. 24:90-99(2014).
RN   [15]
RP   INTERACTION WITH ISCA1.
RX   PubMed=26569474; DOI=10.1038/nmat4484;
RA   Qin S., Yin H., Yang C., Dou Y., Liu Z., Zhang P., Yu H., Huang Y.,
RA   Feng J., Hao J., Hao J., Deng L., Yan X., Dong X., Zhao Z., Jiang T.,
RA   Wang H.W., Luo S.J., Xie C.;
RT   "A magnetic protein biocompass.";
RL   Nat. Mater. 15:217-226(2016).
RN   [16]
RP   INTERACTION WITH HNF4A.
RX   PubMed=30530698; DOI=10.1073/pnas.1816411115;
RA   Qu M., Duffy T., Hirota T., Kay S.A.;
RT   "Nuclear receptor HNF4A transrepresses CLOCK:BMAL1 and modulates tissue-
RT   specific circadian networks.";
RL   Proc. Natl. Acad. Sci. U.S.A. 115:E12305-E12312(2018).
RN   [17]
RP   INTERACTION WITH TIMELESS.
RX   PubMed=31138685; DOI=10.1073/pnas.1819110116;
RA   Kurien P., Hsu P.K., Leon J., Wu D., McMahon T., Shi G., Xu Y., Lipzen A.,
RA   Pennacchio L.A., Jones C.R., Fu Y.H., Ptacek L.J.;
RT   "TIMELESS mutation alters phase responsiveness and causes advanced sleep
RT   phase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 116:12045-12053(2019).
CC   -!- FUNCTION: Transcriptional repressor which forms a core component of the
CC       circadian clock. The circadian clock, an internal time-keeping system,
CC       regulates various physiological processes through the generation of
CC       approximately 24 hour circadian rhythms in gene expression, which are
CC       translated into rhythms in metabolism and behavior. It is derived from
CC       the Latin roots 'circa' (about) and 'diem' (day) and acts as an
CC       important regulator of a wide array of physiological functions
CC       including metabolism, sleep, body temperature, blood pressure,
CC       endocrine, immune, cardiovascular, and renal function. Consists of two
CC       major components: the central clock, residing in the suprachiasmatic
CC       nucleus (SCN) of the brain, and the peripheral clocks that are present
CC       in nearly every tissue and organ system. Both the central and
CC       peripheral clocks can be reset by environmental cues, also known as
CC       Zeitgebers (German for 'timegivers'). The predominant Zeitgeber for the
CC       central clock is light, which is sensed by retina and signals directly
CC       to the SCN. The central clock entrains the peripheral clocks through
CC       neuronal and hormonal signals, body temperature and feeding-related
CC       cues, aligning all clocks with the external light/dark cycle. Circadian
CC       rhythms allow an organism to achieve temporal homeostasis with its
CC       environment at the molecular level by regulating gene expression to
CC       create a peak of protein expression once every 24 hours to control when
CC       a particular physiological process is most active with respect to the
CC       solar day. Transcription and translation of core clock components
CC       (CLOCK, NPAS2, BMAL1, BMAL2, PER1, PER2, PER3, CRY1 and CRY2) plays a
CC       critical role in rhythm generation, whereas delays imposed by post-
CC       translational modifications (PTMs) are important for determining the
CC       period (tau) of the rhythms (tau refers to the period of a rhythm and
CC       is the length, in time, of one complete cycle). A diurnal rhythm is
CC       synchronized with the day/night cycle, while the ultradian and
CC       infradian rhythms have a period shorter and longer than 24 hours,
CC       respectively. Disruptions in the circadian rhythms contribute to the
CC       pathology of cardiovascular diseases, cancer, metabolic syndromes and
CC       aging. A transcription/translation feedback loop (TTFL) forms the core
CC       of the molecular circadian clock mechanism. Transcription factors,
CC       CLOCK or NPAS2 and BMAL1 or BMAL2, form the positive limb of the
CC       feedback loop, act in the form of a heterodimer and activate the
CC       transcription of core clock genes and clock-controlled genes (involved
CC       in key metabolic processes), harboring E-box elements (5'-CACGTG-3')
CC       within their promoters. The core clock genes: PER1/2/3 and CRY1/2 which
CC       are transcriptional repressors form the negative limb of the feedback
CC       loop and interact with the CLOCK|NPAS2-BMAL1|BMAL2 heterodimer
CC       inhibiting its activity and thereby negatively regulating their own
CC       expression. This heterodimer also activates nuclear receptors NR1D1/2
CC       and RORA/B/G, which form a second feedback loop and which activate and
CC       repress BMAL1 transcription, respectively. CRY1 and CRY2 have redundant
CC       functions but also differential and selective contributions at least in
CC       defining the pace of the SCN circadian clock and its circadian
CC       transcriptional outputs. Less potent transcriptional repressor in
CC       cerebellum and liver than CRY1, though less effective in lengthening
CC       the period of the SCN oscillator. Seems to play a critical role in
CC       tuning SCN circadian period by opposing the action of CRY1. With CRY1,
CC       dispensable for circadian rhythm generation but necessary for the
CC       development of intercellular networks for rhythm synchrony. May mediate
CC       circadian regulation of cAMP signaling and gluconeogenesis by blocking
CC       glucagon-mediated increases in intracellular cAMP concentrations and in
CC       CREB1 phosphorylation. Besides its role in the maintenance of the
CC       circadian clock, is also involved in the regulation of other processes.
CC       Plays a key role in glucose and lipid metabolism modulation, in part,
CC       through the transcriptional regulation of genes involved in these
CC       pathways, such as LEP or ACSL4. Represses glucocorticoid receptor
CC       NR3C1/GR-induced transcriptional activity by binding to glucocorticoid
CC       response elements (GREs). Represses the CLOCK-BMAL1 induced
CC       transcription of BHLHE40/DEC1. Represses the CLOCK-BMAL1 induced
CC       transcription of NAMPT (By similarity). Represses PPARD and its target
CC       genes in the skeletal muscle and limits exercise capacity (By
CC       similarity). Represses the transcriptional activity of NR1I2 (By
CC       similarity). {ECO:0000250|UniProtKB:Q9R194,
CC       ECO:0000269|PubMed:10531061, ECO:0000269|PubMed:14672706,
CC       ECO:0000269|PubMed:16790549}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000250|UniProtKB:Q9R194};
CC       Note=Binds 1 FAD per subunit. Only a minority of the protein molecules
CC       contain bound FAD. Contrary to the situation in photolyases, the FAD is
CC       bound in a shallow, surface-exposed pocket.
CC       {ECO:0000250|UniProtKB:Q9R194};
CC   -!- COFACTOR:
CC       Name=(6R)-5,10-methylene-5,6,7,8-tetrahydrofolate;
CC         Xref=ChEBI:CHEBI:15636; Evidence={ECO:0000250};
CC       Note=Binds 1 5,10-methenyltetrahydrofolate (MTHF) non-covalently per
CC       subunit. {ECO:0000250};
CC   -!- ACTIVITY REGULATION: KL001 (N-[3-(9H-carbazol-9-yl)-2-hydroxypropyl]-N-
CC       (2-furanylmethyl)-methanesulfonamide) binds to CRY1 and stabilizes it
CC       by inhibiting FBXL3- and ubiquitin-dependent degradation of CRY1
CC       resulting in lengthening of the circadian periods.
CC       {ECO:0000269|PubMed:22798407}.
CC   -!- SUBUNIT: Component of the circadian core oscillator, which includes the
CC       CRY proteins, CLOCK or NPAS2, BMAL1 or BMAL2, CSNK1D and/or CSNK1E,
CC       TIMELESS, and the PER proteins (By similarity). Interacts with TIMELESS
CC       (PubMed:31138685). Interacts directly with PER1, PER2 and PER3;
CC       interaction with PER2 inhibits its ubiquitination and vice versa (By
CC       similarity). Interacts with CLOCK-BMAL1 (By similarity). Interacts with
CC       CLOCK (By similarity). Interacts with BMAL1 (By similarity). Interacts
CC       with NFIL3 (By similarity). Interacts with FBXL3 (PubMed:17463251).
CC       Interacts with FBXL21 (By similarity). FBXL3, PER2 and the cofactor FAD
CC       compete for overlapping binding sites (By similarity). FBXL3 cannot
CC       bind CRY2 that interacts already with PER2 or that contains bound FAD
CC       (By similarity). Interacts with PPP5C (via TPR repeats); the
CC       interaction down-regulates the PPP5C phosphatase activity on CSNK1E
CC       (PubMed:16790549). Interacts with nuclear receptors AR and NR3C1/GR;
CC       the interaction is ligand dependent (By similarity). Interacts with
CC       PRKDC and CIART (By similarity). Interacts with ISCA1 (in vitro)
CC       (PubMed:26569474). Interacts with DDB1, USP7 and TARDBP (By
CC       similarity). Interacts with HNF4A (PubMed:30530698). Interacts with
CC       PPARA (By similarity). Interacts with PPARD (via domain NR LBD) and
CC       NR1I2 (via domain NR LBD) in a ligand-dependent manner (By similarity).
CC       Interacts with PPARG, NR1I3 and VDR in a ligand-dependent manner (By
CC       similarity). {ECO:0000250|UniProtKB:Q9R194,
CC       ECO:0000269|PubMed:16790549, ECO:0000269|PubMed:17463251,
CC       ECO:0000269|PubMed:26569474, ECO:0000269|PubMed:30530698,
CC       ECO:0000269|PubMed:31138685}.
CC   -!- INTERACTION:
CC       Q49AN0; Q13363-2: CTBP1; NbExp=3; IntAct=EBI-2212355, EBI-10171858;
CC       Q49AN0; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-2212355, EBI-3867333;
CC       Q49AN0; P28799: GRN; NbExp=3; IntAct=EBI-2212355, EBI-747754;
CC       Q49AN0; Q8WZ60: KLHL6; NbExp=5; IntAct=EBI-2212355, EBI-6426464;
CC       Q49AN0; Q6A162: KRT40; NbExp=3; IntAct=EBI-2212355, EBI-10171697;
CC       Q49AN0; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-2212355, EBI-11959885;
CC       Q49AN0; Q8IUG1: KRTAP1-3; NbExp=3; IntAct=EBI-2212355, EBI-11749135;
CC       Q49AN0; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-2212355, EBI-10172290;
CC       Q49AN0; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-2212355, EBI-10171774;
CC       Q49AN0; Q3LI70: KRTAP19-6; NbExp=3; IntAct=EBI-2212355, EBI-12805508;
CC       Q49AN0; Q9BYR5: KRTAP4-2; NbExp=3; IntAct=EBI-2212355, EBI-10172511;
CC       Q49AN0; Q6L8H4: KRTAP5-1; NbExp=3; IntAct=EBI-2212355, EBI-12074540;
CC       Q49AN0; Q701N4: KRTAP5-2; NbExp=3; IntAct=EBI-2212355, EBI-11958178;
CC       Q49AN0; Q6L8H1: KRTAP5-4; NbExp=3; IntAct=EBI-2212355, EBI-11963072;
CC       Q49AN0; Q6L8G8: KRTAP5-7; NbExp=3; IntAct=EBI-2212355, EBI-11987425;
CC       Q49AN0; P26371: KRTAP5-9; NbExp=3; IntAct=EBI-2212355, EBI-3958099;
CC       Q49AN0; Q9BYQ0: KRTAP9-8; NbExp=3; IntAct=EBI-2212355, EBI-11958364;
CC       Q49AN0; O15344: MID1; NbExp=3; IntAct=EBI-2212355, EBI-2340316;
CC       Q49AN0; Q5JR59: MTUS2; NbExp=3; IntAct=EBI-2212355, EBI-742948;
CC       Q49AN0; Q5JR59-3: MTUS2; NbExp=5; IntAct=EBI-2212355, EBI-11522433;
CC       Q49AN0; O95544: NADK; NbExp=3; IntAct=EBI-2212355, EBI-743949;
CC       Q49AN0; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-2212355, EBI-22310682;
CC       Q49AN0; O76083: PDE9A; NbExp=3; IntAct=EBI-2212355, EBI-742764;
CC       Q49AN0; O76083-2: PDE9A; NbExp=3; IntAct=EBI-2212355, EBI-11524542;
CC       Q49AN0; Q9NRD5: PICK1; NbExp=3; IntAct=EBI-2212355, EBI-79165;
CC       Q49AN0; P53041: PPP5C; NbExp=3; IntAct=EBI-2212355, EBI-716663;
CC       Q49AN0; P0C264: SBK3; NbExp=3; IntAct=EBI-2212355, EBI-17181801;
CC       Q49AN0; Q9H190: SDCBP2; NbExp=3; IntAct=EBI-2212355, EBI-742426;
CC       Q49AN0; Q13077: TRAF1; NbExp=3; IntAct=EBI-2212355, EBI-359224;
CC       Q49AN0; Q12933: TRAF2; NbExp=3; IntAct=EBI-2212355, EBI-355744;
CC       Q49AN0; Q2TAL6: VWC2; NbExp=3; IntAct=EBI-2212355, EBI-11957238;
CC       Q49AN0; Q9H0D6: XRN2; NbExp=3; IntAct=EBI-2212355, EBI-372110;
CC       Q49AN0; B2RXF5: ZBTB42; NbExp=3; IntAct=EBI-2212355, EBI-12287587;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9801304}. Nucleus
CC       {ECO:0000269|PubMed:22798407, ECO:0000269|PubMed:9801304}.
CC       Note=Translocated to the nucleus through interaction with other Clock
CC       proteins such as PER2 or BMAL1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q49AN0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q49AN0-2; Sequence=VSP_038970;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined including fetal
CC       brain, fibroblasts, heart, brain, placenta, lung, liver, skeletal
CC       muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary,
CC       small intestine, colon and leukocytes. Highest levels in heart and
CC       skeletal muscle. {ECO:0000269|PubMed:8909283,
CC       ECO:0000269|PubMed:9801304}.
CC   -!- PTM: Phosphorylation on Ser-266 by MAPK is important for the inhibition
CC       of CLOCK-BMAL1-mediated transcriptional activity. Phosphorylation by
CC       CSKNE requires interaction with PER1 or PER2. Phosphorylated in a
CC       circadian manner at Ser-554 and Ser-558 in the suprachiasmatic nucleus
CC       (SCN) and liver. Phosphorylation at Ser-558 by DYRK1A promotes
CC       subsequent phosphorylation at Ser-554 by GSK3-beta: the two-step
CC       phosphorylation at the neighboring Ser residues leads to its
CC       proteasomal degradation. {ECO:0000250|UniProtKB:Q9R194}.
CC   -!- PTM: Ubiquitinated by the SCF(FBXL3) and SCF(FBXL21) complexes,
CC       regulating the balance between degradation and stabilization. The
CC       SCF(FBXL3) complex is mainly nuclear and mediates ubiquitination and
CC       subsequent degradation of CRY2. In contrast, cytoplasmic SCF(FBXL21)
CC       complex-mediated ubiquitination leads to stabilize CRY2 and counteract
CC       the activity of the SCF(FBXL3) complex. The SCF(FBXL3) and SCF(FBXL21)
CC       complexes probably mediate ubiquitination at different Lys residues.
CC       The SCF(FBXL3) complex recognizes and binds CRY2 phosphorylated at Ser-
CC       554 and Ser-558. Ubiquitination may be inhibited by PER2.
CC       Deubiquitinated by USP7 (By similarity). {ECO:0000250|UniProtKB:Q9R194,
CC       ECO:0000269|PubMed:11889036, ECO:0000269|PubMed:17463251,
CC       ECO:0000269|PubMed:22798407}.
CC   -!- SIMILARITY: Belongs to the DNA photolyase class-1 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH35161.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact. Aberrant splice sites.; Evidence={ECO:0000305};
CC       Sequence=BAG57993.1; Type=Erroneous termination; Note=Truncated C-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG57993.1; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305};
CC       Sequence=BAG64048.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Cryptochrome entry;
CC       URL="https://en.wikipedia.org/wiki/Cryptochrome";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK294904; BAG57993.1; ALT_SEQ; mRNA.
DR   EMBL; AK302865; BAG64048.1; ALT_INIT; mRNA.
DR   EMBL; AC068385; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF455380; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035161; AAH35161.1; ALT_SEQ; mRNA.
DR   EMBL; BC041814; AAH41814.1; -; mRNA.
DR   EMBL; AB014558; BAA31633.1; -; mRNA.
DR   CCDS; CCDS44576.1; -. [Q49AN0-2]
DR   CCDS; CCDS7915.3; -. [Q49AN0-1]
DR   RefSeq; NP_001120929.1; NM_001127457.2. [Q49AN0-2]
DR   RefSeq; NP_066940.2; NM_021117.3. [Q49AN0-1]
DR   AlphaFoldDB; Q49AN0; -.
DR   SMR; Q49AN0; -.
DR   BioGRID; 107798; 196.
DR   ComplexPortal; CPX-3220; Cry2-Per2 complex.
DR   ComplexPortal; CPX-3221; Cry2-Per1 complex.
DR   ComplexPortal; CPX-3224; Cry2-Per3 complex.
DR   CORUM; Q49AN0; -.
DR   DIP; DIP-47396N; -.
DR   IntAct; Q49AN0; 50.
DR   MINT; Q49AN0; -.
DR   STRING; 9606.ENSP00000478187; -.
DR   BindingDB; Q49AN0; -.
DR   ChEMBL; CHEMBL4296116; -.
DR   iPTMnet; Q49AN0; -.
DR   PhosphoSitePlus; Q49AN0; -.
DR   BioMuta; CRY2; -.
DR   DMDM; 118572252; -.
DR   EPD; Q49AN0; -.
DR   jPOST; Q49AN0; -.
DR   MassIVE; Q49AN0; -.
DR   MaxQB; Q49AN0; -.
DR   PaxDb; Q49AN0; -.
DR   PeptideAtlas; Q49AN0; -.
DR   ProteomicsDB; 62059; -. [Q49AN0-1]
DR   ProteomicsDB; 62060; -. [Q49AN0-2]
DR   Antibodypedia; 26186; 292 antibodies from 34 providers.
DR   DNASU; 1408; -.
DR   Ensembl; ENST00000417225.6; ENSP00000397419.2; ENSG00000121671.12. [Q49AN0-2]
DR   Ensembl; ENST00000616080.2; ENSP00000484684.1; ENSG00000121671.12. [Q49AN0-1]
DR   GeneID; 1408; -.
DR   KEGG; hsa:1408; -.
DR   MANE-Select; ENST00000616080.2; ENSP00000484684.1; NM_021117.5; NP_066940.3.
DR   UCSC; uc009ykw.4; human. [Q49AN0-1]
DR   AGR; HGNC:2385; -.
DR   CTD; 1408; -.
DR   DisGeNET; 1408; -.
DR   GeneCards; CRY2; -.
DR   HGNC; HGNC:2385; CRY2.
DR   HPA; ENSG00000121671; Low tissue specificity.
DR   MIM; 603732; gene.
DR   neXtProt; NX_Q49AN0; -.
DR   OpenTargets; ENSG00000121671; -.
DR   PharmGKB; PA26905; -.
DR   VEuPathDB; HostDB:ENSG00000121671; -.
DR   eggNOG; KOG0133; Eukaryota.
DR   GeneTree; ENSGT00940000159073; -.
DR   HOGENOM; CLU_010348_3_4_1; -.
DR   InParanoid; Q49AN0; -.
DR   OrthoDB; 124765at2759; -.
DR   PhylomeDB; Q49AN0; -.
DR   TreeFam; TF323191; -.
DR   PathwayCommons; Q49AN0; -.
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   SABIO-RK; Q49AN0; -.
DR   SignaLink; Q49AN0; -.
DR   SIGNOR; Q49AN0; -.
DR   BioGRID-ORCS; 1408; 15 hits in 1163 CRISPR screens.
DR   ChiTaRS; CRY2; human.
DR   GenomeRNAi; 1408; -.
DR   Pharos; Q49AN0; Tbio.
DR   PRO; PR:Q49AN0; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q49AN0; protein.
DR   Bgee; ENSG00000121671; Expressed in hindlimb stylopod muscle and 186 other tissues.
DR   ExpressionAtlas; Q49AN0; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; IDA:MGI.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0009882; F:blue light photoreceptor activity; NAS:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0071949; F:FAD binding; ISS:UniProtKB.
DR   GO; GO:0016922; F:nuclear receptor binding; IEA:Ensembl.
DR   GO; GO:0019902; F:phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISS:UniProtKB.
DR   GO; GO:0009785; P:blue light signaling pathway; NAS:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0042754; P:negative regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:2000323; P:negative regulation of glucocorticoid receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:2000850; P:negative regulation of glucocorticoid secretion; IEA:Ensembl.
DR   GO; GO:0032515; P:negative regulation of phosphoprotein phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:2000118; P:regulation of sodium-dependent phosphate transport; IDA:MGI.
DR   GO; GO:0014823; P:response to activity; ISS:UniProtKB.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0009416; P:response to light stimulus; IMP:CAFA.
DR   DisProt; DP00473; -.
DR   Gene3D; 1.25.40.80; -; 1.
DR   Gene3D; 1.10.579.10; DNA Cyclobutane Dipyrimidine Photolyase, subunit A, domain 3; 1.
DR   Gene3D; 3.40.50.620; HUPs; 1.
DR   InterPro; IPR036134; Crypto/Photolyase_FAD-like_sf.
DR   InterPro; IPR036155; Crypto/Photolyase_N_sf.
DR   InterPro; IPR005101; Cryptochr/Photolyase_FAD-bd.
DR   InterPro; IPR002081; Cryptochrome/DNA_photolyase_1.
DR   InterPro; IPR006050; DNA_photolyase_N.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   PANTHER; PTHR11455; CRYPTOCHROME; 1.
DR   PANTHER; PTHR11455:SF15; CRYPTOCHROME-2; 1.
DR   Pfam; PF00875; DNA_photolyase; 1.
DR   Pfam; PF03441; FAD_binding_7; 1.
DR   SUPFAM; SSF48173; Cryptochrome/photolyase FAD-binding domain; 1.
DR   SUPFAM; SSF52425; Cryptochrome/photolyase, N-terminal domain; 1.
DR   PROSITE; PS51645; PHR_CRY_ALPHA_BETA; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Biological rhythms; Chromophore; Cytoplasm; FAD;
KW   Flavoprotein; Isopeptide bond; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Photoreceptor protein; Receptor; Reference proteome; Repressor;
KW   Sensory transduction; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN           1..593
FT                   /note="Cryptochrome-2"
FT                   /id="PRO_0000261148"
FT   DOMAIN          22..151
FT                   /note="Photolyase/cryptochrome alpha/beta"
FT   REGION          390..489
FT                   /note="Required for inhibition of CLOCK-BMAL1-mediated
FT                   transcription"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   REGION          532..593
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        533..547
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        561..580
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         271
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   BINDING         308
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   BINDING         374
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   BINDING         406..408
FT                   /ligand="FAD"
FT                   /ligand_id="ChEBI:CHEBI:57692"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   MOD_RES         90
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOD_RES         266
FT                   /note="Phosphoserine; by MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   MOD_RES         299
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   MOD_RES         554
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   MOD_RES         558
FT                   /note="Phosphoserine; by DYRK1A and MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   CROSSLNK        30
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P97784"
FT   CROSSLNK        126
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   CROSSLNK        242
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   CROSSLNK        348
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   CROSSLNK        475
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   CROSSLNK        504
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R194"
FT   VAR_SEQ         1..72
FT                   /note="MAATVATAAAVAPAPAPGTDSASSVHWFRKGLRLHDNPALLAAVRGARCVRC
FT                   VYILDPWFAASSSVGINRWR -> MPAPPGRTHTW (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_038970"
FT   CONFLICT        422
FT                   /note="S -> G (in Ref. 4; AAH35161)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q49AN0-2:9
FT                   /note="H -> L (in Ref. 2; BAG57993)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   593 AA;  66947 MW;  BF380424092BEBFB CRC64;
     MAATVATAAA VAPAPAPGTD SASSVHWFRK GLRLHDNPAL LAAVRGARCV RCVYILDPWF
     AASSSVGINR WRFLLQSLED LDTSLRKLNS RLFVVRGQPA DVFPRLFKEW GVTRLTFEYD
     SEPFGKERDA AIMKMAKEAG VEVVTENSHT LYDLDRIIEL NGQKPPLTYK RFQAIISRME
     LPKKPVGLVT SQQMESCRAE IQENHDETYG VPSLEELGFP TEGLGPAVWQ GGETEALARL
     DKHLERKAWV ANYERPRMNA NSLLASPTGL SPYLRFGCLS CRLFYYRLWD LYKKVKRNST
     PPLSLFGQLL WREFFYTAAT NNPRFDRMEG NPICIQIPWD RNPEALAKWA EGKTGFPWID
     AIMTQLRQEG WIHHLARHAV ACFLTRGDLW VSWESGVRVF DELLLDADFS VNAGSWMWLS
     CSAFFQQFFH CYCPVGFGRR TDPSGDYIRR YLPKLKAFPS RYIYEPWNAP ESIQKAAKCI
     IGVDYPRPIV NHAETSRLNI ERMKQIYQQL SRYRGLCLLA SVPSCVEDLS HPVAEPSSSQ
     AGSMSSAGPR PLPSGPASPK RKLEAAEEPP GEELSKRARV AELPTPELPS KDA
//
